Elevation of acetylcholine levels in striatum of rat brain by LY163502, trans−(−)−5,5a,6,7,8,9a,10-octahydro-6-propylpyrimido〈4,5−g〉quinolin-2- amine dihydrochloride, a potent and stereospecific dopamine (D 2) agonist

Abstract

LY163502, a partial ergoline and a trans-levorotatory enantiomer, does not stimulate adenylate cyclase in striatal membranes but inhibits 50% binding of 3H-apomorphine, 3H-pergolide and 3H-spiperone at 10, 13 and 151 nM (IC 50), respectively. The racemic mixture (LY137157) is less effective, with 3, 2.7 and 1.4 times higher IC 50 values, respectively, whereas the dextrorotatory isomer (LY175877) is inactive. LY163502 inhibits binding of 3H-clonidine with an IC 50 value of 2600 nM, but not the binding of 3H-WB4101, 3H-dihydroalprenolol, 3H-serotonin, 3H-quinuclidinyl benzilate and 3H-pyramilamine or the uptake of serotonin, norepinephrine or dopamine, suggesting selective affinity toward dopamine receptors in vitro . Both LY163502 and LY137157 elevate striatal acetylcholine (Ach) levels. The elevation of Ach levels by LY163502 is reversed by dopamine antagonists haloperidol, cis -flupenthixol and metoclopramide. Therefore, the levorotatory enantiomer exhibits pharmacology of a D 2 type of dopamine agonist.